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Abstract
Background: Stem cell injection therapies have been proposed to overcome the limited efficacy and adverse
reactions of bulking agents. However, most have significant limitations, including painful procurement, requirement
for anesthesia, donor site infection and a frequently low cell yield. Recently, human amniotic fluid stem cells
(hAFSCs) have been proposed as an ideal cell therapy source. In this study, we investigated whether periurethral
injection of hAFSCs can restore urethral sphincter competency in a mouse model.
Methods: Amniotic fluids were collected and harvested cells were analyzed for stem cell characteristics and in vitro
myogenic differentiation potency. Mice underwent bilateral pudendal nerve transection to generate a stress urinary
incontinence (SUI) model and received either periurethral injection of hAFSCs, periurethral injection of Plasma-Lyte
(control group), or underwent a sham (normal control group).
For in vivo cell tracking, cells were labeled with silica-coated magnetic nanoparticles containing rhodamine B
isothiocyanate (MNPs@SiO2 (RITC)) and were injected into the urethral sphincter region (n = 9). Signals were
detected by optical imaging. Leak point pressure and closing pressure were recorded serially after injection.
Tumorigenicity of hAFSCs was evaluated by implanting hAFSCs into the subcapsular space of the kidney, followed
two weeks later by retrieval and histologic analysis.
Results: Flow activated cell sorting showed that hAFSCs expressed mesenchymal stem cell (MSC) markers, but no
hematopoietic stem cell markers. Induction of myogenic differentiation in the hAFSCs resulted in expression of
PAX7 and MYOD at Day 3, and DYSTROPHIN at Day 7. The nanoparticle-labeled hAFSCs could be tracked in vivo
with optical imaging for up to 10 days after injection. Four weeks after injection, the mean LPP and CP were
significantly increased in the hAFSC-injected group compared with the control group. Nerve regeneration and
neuromuscular junction formation of injected hAFSCs in vivo was confirmed with expression of neuronal markers
and acetylcholine receptor. Injection of hAFSCs caused no in vivo host CD8 lymphocyte aggregation or tumor
formation.
Conclusions: hAFSCs displayed MSC characteristics and could differentiate into cells of myogenic lineage.
Periurethral injection of hAFSCs into an SUI animal model restored the urethral sphincter to apparently normal
histology and function, in absence of immunogenicity and tumorigenicity.
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Background
Stress urinary incontinence (SUI), defined as the involun-
tary leakage of urine upon physical activity, sneezing or
coughing, is an embarrassing problem in women [1].
Treatment modalities for SUI include pharmacotherapy,
surgery and injection of bulking agents. Surgical
approaches, such as tension free vaginal tape, transobtura-
tor slings or pubovaginal slings, remain the gold standards
for SUI treatment. The efficacy of pharmacotherapy for
SUI has been disappointing. Attempts to avoid invasive
surgery and morbidity have included the use of various
injectable bulking agents, including polytetrafluoroethy-
lene, bovine collagen, silicone particles, carbon beads and
autologous fat or chondrocytes [2]. However, these proce-
dures have had limited success and frequent adverse
reactions, such as allergic and immune reactions, infection,
particle migration and reabsorption of injected bulking
agents [2].
Stem cell therapy has been proposed as an attractive
alternative to overcome the limitations and side effects of
pharmacotherapeutic procedures [3-6]. One of the most
commonly used cell types are bone marrow stromal cells
[4]. However, bone marrow procurement requires general
or spinal anesthesia, and yields a low number of stem cells
upon processing. Muscle derived stem cells and adipose
derived stem cells have been proposed as alternative cell
sources [5,6]. Although these cells can be obtained in large
quantities under local anesthesia, procurement remains an
invasive procedure with the risk of morbidity. Recently, we
reported the use of human amniotic fluid stem cells
(hAFSCs), which can be obtained non-invasively, have a
high proliferation rate, induce immune tolerance, display
embryonic stem cell properties and are able to differenti-
ate into cells representing all three embryonic germ layers
[7]. These characteristics suggest hAFSCs might be an
ideal cell source for stem cell therapy applications.
The primary objective of this study was to investigate
whether periurethral injection of hAFSCs results in
restoration of the urethral sphincter to normal histology
and function. Secondary objectives were to characterize
hAFSCs stem cell properties and myogenicity in vitro, to
develop a non-invasive method for tracking injected
cells, and to evaluate in vivo viability, immunogenicity
and tumorigenicity of transplanted hAFSCs.
Methods
Isolation and culture of hAFSCs
This study was approved by the Ethics Committee of
Kyungpook National University School of Medicine. All
participants provided informed consent. Amniotic fluids
(10 mL each) were obtained from four women undergoing
routine amniocentesis at a gestational age of 15 to 19
weeks. Amniotic fluids were centrifuged and supernatants
discarded. Cell pellets were resuspended with Chang Med-
ium (a-MEM, 15% embryonic stem cell-fetal bovine
serum (Gibco-Invitrogen, Grand Island, NY, USA) with
18% Chang B and 2% Chang C (Irvine Scientific, Irvine,
CA, USA)} in a petri dish. Non-adherent cells were dis-
carded after one week. Adherent cells were passaged for
expansion on reaching 80% confluence, and culture med-
ium was replaced every three days.
Characterization of hAFSCs
hAFSCs (Passage 3) were evaluated by flow cytometry
with phycoerythrin (PE)- or fluorescein isothiocyanate-
conjugated mouse monoclonal antibodies specific for
embryonic stem cell marker SSEA4, MSC markers
CD44, CD73, CD90 and CD105, hematopoietic stem
cell marker CD45, and immunologic markers HLA-ABC
and HLA-DR (BD Biosciences, San Jose, CA, USA),
according to the manufacturer’s instructions. Approxi-
mately 10,000 cells were measured using a fluorescence
activated cell sorter (FACS; BD Biosciences) system
equipped with the CellQuest program. A homogenous
stem cell population was obtained by sorting the cells
twice using C-KIT antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) with a magnetic activated cell
sorting system (MACS, Miltenyi Biotec, Bergischu Glad-
bach, Germany). In case #1, a cell population with high
expression for C-KIT and SSEA4 as well as low expres-
sion for HLA-DR was obtained and used for subsequent
studies.
Myogenic differentiation of hAFSCs in vitro
The optimum myogenic condition for hAFSC induction
was determined by testing three different induction
media: (i) myogenic medium (DMEM, 0.5% chick
embryo extract, 10% horse serum, Gibco-Invitrogen)
containing 3 μM of 5-aza-20-deoxycytidine (5-azaC;
Sigma-Aldrich, St. Louis, MO, USA), (ii) myogenic med-
ium containing 5 ng/mL of transforming growth factor-
b (TGF-b; Peprotech, Rocky Hill, NJ, USA), and (iii)
conditioned medium (CM; collected from cultured
human skeletal muscle cells). After 24-hour treatment
with 5-azaC or TGF-b, cells were cultured up to a
further 14 days. Cell viabilities at 1, 3, 5 and 14 days of
differentiation were measured using a CCK-8 assay kit
(Dojindo, Kumamoto, Japan,) according to the manufac-
turer’s instructions. The genotypic and morphologic
conversion of hAFSC into myocytes was analyzed by
real-time polymerase chain reaction (PCR) and immu-
nocytochemical (ICC) staining using routine methods.
The primer sequences and antibody information are
listed in Tables 1 and 2, respectively. The C2C12 cell
line and human fibroblasts served as positive and nega-
tive controls for ICC staining respectively. The same
experiment was repeated three times independently.
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Generation of an incompetent urethral sphincter model
All experimental protocols were approved by the Animal
Ethics Committee, Kyungpook National University
School of Medicine. Female imprinting control region
(ICR) mice, weighing 20 to 25 g, were obtained from
Hyochang Science (Daegu, Korea). Animals were pre-
pared for aseptic surgery under general anesthesia (iso-
flurane). A lower midline abdominal incision was made
and the bladder and urethra were exposed. The SUI
model was created using a bilateral pudendal nerve
transection technique instead of crush injury of the
pudendal nerve. This allowed us to confirm the func-
tional recovery of incontinence by regeneration of the
urethral sphincter and to eliminate the effect of puden-
dal nerve regeneration. The pudendal nerve on each
side was identified and transected with microsurgical
scissors under microscopic magnification (n = 30).
Laparotomy was closed in layers with absorbable 4 to 0
vicryl sutures. An additional 15 mice underwent a sham
operation (lower midline incision and closure) and
served as normal controls.
Injection of hAFSCs
One week after generation of the incompetent urethral
sphincter model, animals were anesthetized with isoflur-
ane and the bladder and urethra were exposed by a
lower abdominal incision. The urethra was slightly
retracted and hAFSCs were injected at the three and
nine o’clock area of the external sphincter using a 26G






























Table 2 Antibody information for ICC, IHC and FACS analysis
Antibody Company Dilution
MYOD Myogenic determination Santa Cruz Biotechnology 1:300
DES desmin Abcam 1:300
a-SM ACTIN alpha smooth muscle actin Santa Cruz Biotechnology 1:300
MHC Myosin heavy chain Santa Cruz Biotechnology 1:300
a-ACTININ alpha actinin Sigma-Aldrich 1:300
CD8 cluster of differentiation 8 Chemicon 1:200
SSEA4 stage-specific embryonic antigen4 BD Pharmingen 1:20
C-KIT(CD117) cluster of differentiation117 BD Pharmingen 1:20
CD44 cluster of differentiation44 BD Pharmingen 1:20
CD45 cluster of differentiation45 BD Pharmingen 1:20
CD73 cluster of differentiation73 BD Pharmingen 1:20
CD90 cluster of differentiation90 BD Pharmingen 1:20
CD105 cluster of differentiation105 Abcam 1:20
HLA-ABC human leukocyte antigen-ABC BD Pharmingen 1:20
HLA-DR human leukocyte antigen-DR BD Pharmingen 1:20
HuNu human nuclear-specific Cell Signaling 1:100
a-Bungarotoxin a-Bungarotoxin Invitrogen 1:100
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Hamilton microsyringe (Hamilton Company, Reno, NV,
USA). The depth of injection was determined by an
experienced operator. Each injection consisted of 0.5 × 106
undifferentiated AFSCs (Passage 5) in 5 μL of Plasma-Lyte.
Three experimental groups were established: a sham-
operation group (Ctrl), a pudendal neurectomy without
cell injection group (Cell (-)) and a pudendal neurectomy
with cell injection group (Cell (+)) (n = 15 for each group).
The fate of injected cells in vivo was traced by immunohis-
tochemical (IHC) staining with human nuclear-specific
antibody at 3, 5, 7 and 14 days after injection.
MNPs@SiO2 labeling of hAFSCs and in vivo tracking
Silica-coated magnetic nanoparticles incorporating rhoda-
mine B isothiocyanate (MNPs@SiO2 (RITC)) were kindly
provided by Dr. Jae-sung Bae (Kyungpook National
University, Daegu, Korea). MNPs@SiO2 (RITC) is a novel
cell-tracking agent with multimodal fluorescence and
magnetic properties. MNPs@SiO2 (RITC) nanoparticles
become integrated into the cells by endocytosis. The nano-
particles are not shed by cells and the signal cannot be
detected after cell death. When cells are proliferating or
differentiating, MNPs@SiO2 (RITC) transfers into daugh-
ter cells, where each cell particle number becomes gradu-
ally reduced. MNPs@SiO2 (RITC) is biocompatible and
has been used for various stem cell tracking studies [8-10].
In the present study, the optimal concentration and expo-
sure time of MNPs@SiO2 (RITC) for efficient uptake of
nanoparticles into AFSCs was established by incubating
cells at 37°C with various concentrations (0.01, 0.05, 0.1 or
0.2 mg/mL) of MNPs@SiO2 (RITC) for different exposure
times (24 to 72 hours). Briefly, the AFSCs (2 × 104 per
chamber well) were cultured in Lab-Tek™ Chamber
Slides (four-chamber mounted Permanox slides; Nunc,
Rochester, NY, USA). On reaching about 60 to 70%
confluence, cells were incubated with MNPs@SiO2 (RITC)
in a 37°C/5% CO2 incubator. Labeling was stopped by
washing the cells three times with PBS. Cells were then
fixed by incubation with 4% paraformaldehyde for 20 min-
utes at 4°C and washed with PBS. Individual coverslips
were mounted onto VECTASHIELD mounting medium
with DAPI (Vector Laboratories, Burlingame, CA, USA).
Cells were examined with a fluorescence microscope
(Olympus BX51, Tokyo, Japan) and confocal microscope
(Olympus FluoViewTM FV1000) to determine the intra-
cellular localization of nanoparticles.
For in vivo cell tracking, unsorted MNPs@SiO2 (NIR-
797) labeled cells (0.5 × 106) were injected into the ure-
thral sphincter region of mice (n = 9), and optical images
were obtained at 3, 7, 10 and 14 days using Optix exPlore
(ART, Montreal, QC, Canada) with the filter set for
NIR797. Images were corrected for background and auto-
fluorescence using non-labeled cells as controls. Acquired
images were analyzed with eXplore Optix OptiView
software. For optical imaging, the animal was anesthetized
by intravenous injection of a Rompun (Bayer, Leverkusen,
Germany):Zoletil (Virbac Australia, Milperra NSW, Aus-
tralia):saline mixture (1:5.7:10; 100 μL/mouse) according
to the manufacturers’ guidelines.
Measurement of leak point pressure (LPP) and closing
pressure (CP)
Mice were placed under general anesthesia with ether to
avoid muscle relaxation. LPP and CP were measured one,
two and four weeks after cell injection using the vertical
tilt/intravesical pressure clamp model of SUI as previously
described [11], and the Power Lab® system (AD Instru-
ments Pty Ltd, Bella Vista NSW, Australia). Before mea-
suring, the spinal cord was transected at the T9 to T10
level to eliminate reflex bladder activity in response to
increasing intravesical pressure. This suprasacral spinal
cord transection does not interfere with the spinal conti-
nence reflexes of the bladder neck and urethra [12]. Under
general anesthesia, the bladder was exposed by a midline
incision. A transvesical catheter with a fire-flared tip (PE-
25) was inserted into the dome of the bladder and the
abdominal wall and overlying skin were closed with
sutures. The mice were then mounted on a tilt table and
placed in the vertical position. The intravesical pressure
was clamped by connecting a large 50 mL syringe reser-
voir to the bladder catheter and the pressure transducer
using PE-50 tubing and three-way stopcocks. The intrave-
sical pressure was increased in 1- to 3-cm H2O steps from
0 cm H2O upward until visual identification of the leak
point height. The pressure at this leak point was referred
to as the LPP. The intravesical pressure was then
decreased in 1- to 3-cm H2O steps downward until the
leak ceased. The pressure at this leak cessation point was
taken as the CP. The averages of three consecutive LPP
and CP measurements were taken as data points for each
animal.
Histological, IHC, and real-time PCR analysis
Animals were sacrificed after LPP and CP measurement
and the bladder-urethra complex was removed en bloc.
Tissue specimens were fixed in 10% buffered formalin,
processed and cut into 4- to 6-μM-thick sections for rou-
tine staining with hematoxylin and eosin (H&E), and for
IHC staining. The presence and migration of injected cells
in situ were analyzed by IHC using human nuclear specific
antibody (HuNu; Cell Signaling Technology, Danvers, MA,
USA). Myogenic conversion of injected hAFSCs in vivo
was confirmed with real-time PCR using human primers
for myogenic lineage markers. To investigate whether
injected hAFSCs induced a host myogenic response, real-
time PCR analysis was performed using mouse primers for
myogenic lineage markers. The neuromuscular junction
formation was analyzed at Week 4 by IHC staining for the
Kim et al. BMC Medicine 2012, 10:94
http://www.biomedcentral.com/1741-7015/10/94
Page 4 of 14
acetylcholine receptor with a-Bungarotoxin. The possibi-
lity that hAFSC injection induced host neuroregeneration
was investigated by real-time PCR with mouse neuro-
genic-related primers.
Immunogenicity and tumorigenicity of hAFSCs
The immunogenicity of hAFSCs was evaluated by flow
cytometry to determine expression of HLA-DR on the cell
surface. The in vivo immunosuppression effect of hAFSCs
was examined by retrieving tissue one week after injection
and performing IHC staining with cytotoxic T cell marker
(CD8, BD Pharmigen, San Jose, CA, USA). As a negative
control, human fibroblasts were injected (n = 3). Tumori-
genicity was analyzed by injecting 1 × 106 hAFSCs into
the subcapsular space of the kidney (n = 9). Animals were
sacrificed eight weeks later and kidneys were harvested for
histologic confirmation.
Statistical analysis
Our main outcome measure was to compare differences
between LPP and CP between the hAFSCs injection and
control groups in the SUI animal model. We collected
data from five animals in each group at one, two and four
weeks after injection. The results were also compared with
those of the normal control (n = 5, at each time point).
Data were presented as means ± SD. Statistical analysis
was undertaken with Student’s t-test or one-way analysis
of variance (ANOVA). A P-value of less than 0.05 was
considered statistically significant. When the value was
found to be significant after assessment using the ANOVA
statistical test, the Tukey post-hoc comparison was used.
Results
Characterization of human amniotic fluid cells and
isolation of c-kit C-KIT (+) cells
We obtained adherent cells from all four amniotic fluid
samples. FACS analysis on culture-expanded cells (Passage
3) showed the cells were strongly positive for the mesench-
ymal markers, CD44, CD73, CD90 and CD105; weakly
positive for the embryonic marker, SSEA-4; and negative
for the hematopoietic lineage marker, CD45 and MHC
Class II antigen, HLA-DR (Figure 1A). Double MACS ana-
lysis showed 98.40% of the cell population in case #1 was
C-KIT (+) (Figure 1B). The C-KIT (+) populations in other
cases were less than 90% (data not shown). Therefore, we
used the C-KIT (+) cells from case #1 for subsequent
studies.
Myogenic differentiation potential of hAFSCs in vitro
When hAFSCs were cultured in myogenic induction
media, the cells become elongated and with spindle
shapes at Day 7. These findings were similar in all three
groups. CCK-8 assays, performed at Day 14 showed a
2.7- (P < 0.0001) and 1.58- (P < 0.0001) fold higher cell
viability for cells cultured in CM compared with cells
cultured in medium containing 5-azaC or TGF-b,
respectively (Figure 2A). Real-time PCR showed that
expression of early myogenic differentiation markers
(PAX7 and MYOD) was dominant at Day 3, whereas the
mid to late myogenic marker (DYSTROPHIN) became
dominant at Day 7. Each gene expression level varied
depending on the medium type (Figure 2B). These
results were confirmed by ICC staining (Figure 2C).
In vivo identification of injected cells
In vitro ICC staining with HuNu confirmed the presence
of hAFSCs (Figure 3A). IHC staining confirmed focal
detection of injected cells at the injection site at Day 3.
Cells then migrated into the surrounding urethral
sphincter region (Figure 3B). The cell signal decreased
from Day 7 and had disappeared by Day 14.
Optical imaging for in vivo tracking of injected cells
The optimum concentration and treatment time for
MNPs@SiO2 (RITC) labeling of hAFSCs were 0.1 mg/
mL and 24 hours, respectively (Figure 4A). The maxi-
mum labeling efficacy was 94.31% (Figure 4B).
MNPs@SiO2 (RITC) uptake was uniform for each cell
preparation and density. The cell viability assay con-
firmed that the nanoparticles did not induce cytotoxicity
at a wide range of concentrations (0.05 to 0.2 mg/mL)
and exposure times (up to 72 hours) (Figure 4C). Injec-
tion of MNPs@SiO2 (RITC) labeled hAFSCs into the
periurethral region confirmed that optical imaging could
identify these cell clusters at the injection site. The sig-
nal intensity decreased gradually until Day 10 after
injection and disappeared thereafter (Figure 4D).
LPP and CP measurement
LPP and CP were measured one, two and four weeks after
injection (Figure 5). The mean LPP and CP for the Cell
(+) group were similar to those of the Cell (-) group at
Week 1 (17.9 ± 0.5 vs. 16.6 ± 2.1 and 9.9 ± 1.3 vs. 9.1 ± 0.9
cmH2O). However, the mean LPP was significantly higher
for the Cell (+) group than for the Cell (-) group at Week
2 (18.1 ± 2.8 vs. 11.6 ± 1.2 cmH2O, P = 0.0014) and Week
4 (20.2 ± 3.3 vs. 15.2 ± 2.1 cmH2O, P = 0.0202). The mean
CP for the Cell (+) and Cell (-) groups showed similar dif-
ferences to those found for LPP at the same time points
(Week 2: 12.4 ± 1.7 vs. 6.9 ± 1.1 cmH2O, P = 0.0001 and
Week 4: 14.4 ± 3.4 vs. 8.4 ± 1.1 cmH2O, P = 0.0051).
Histological, IHC and real-time PCR analysis
After measurement of LPP and CP, the mice were sacri-
ficed and the whole urethra was excised. The entire
length of the urethra was about 7 mm and the rhabdo-
sphincter was located about 6 mm distant from external
urethral orifice (Figure 6A). H&E staining identified
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normal-appearing circular muscle mass regeneration
over time at the urethral sphincter region in the Cell (+)
group. In contrast, the Cell (-) group showed only scant
muscle regeneration and an atrophic sphincter. These
results were confirmed with IHC staining using MyoD
antibody (Figure 6B). Real-time PCR analysis showed
that the expression of genes related to early (PAX7,
MYF5 and MYOD) and mid to late (MYOGENIN, MEF2
and MLP) myogenic differentiations corresponded cor-
rectly with time. Human gene expression was highest in
the first week then gradually reduced (Figure 7A),
whereas mouse gene expression gradually increased with
time (Figure 7B). The IHC for neuromuscular junction
formation showed that the Cell (+) group had a similar
expression level of a-bungarotoxin for acetylcholine
receptor as the normal control (Figure 7C). Real-time
PCR showed neurogenic gene expression (Nestin,
Vimentin, Neurofilament, Microtubule-associated Pro-
tein 2, b-Tubulin III, Glial Fibrillary Acidic Protein) was
significantly higher (P < 0.05) in the Cell (+) group com-
pared with the Cell (-) group (Figure 7D).
Immunogenicity and tumorigenicity of hAFSCs
FACS analysis showed that HLA-DR expression in
hAFSCs was lower (0.26% total) than that of the isotype
control (1.48% total) (Figure 8A). IHC staining of the
urethral sphincter tissue of hAFSC injected animals
revealed scant CD8 lymphocyte aggregation at one
week, whereas the Cell (-) and human fibroblast injected
animals had significant CD8 lymphocyte accumulation
Figure 1 Characterization of hAFSCs in vitro. (A) FACS analyses for expression of mesenchymal, hematopoietic and immunologic markers.
hAFSCs showed strong positive expression of mesenchymal markers (CD44, CD73, CD90 and CD105), but were negative for the hematopoietic
lineage marker (CD45) and MHC Class II antigen (HLA-DR). (B) Representative FACS image (case #1) of C-KIT (+) cell population after a double
sorting procedure. Approximately 98.4% of cells were C-KIT (+).
Kim et al. BMC Medicine 2012, 10:94
http://www.biomedcentral.com/1741-7015/10/94
Page 6 of 14
(Figure 8B). Histologic analysis revealed no teratoma
formation in tissues retrieved eight weeks after renal
subcapsular injection of hAFSCs (Figure 8C).
Discussion
Stem cell therapies have been proposed for SUI treatment
as a way to overcome the limited efficacy and adverse
reactions attributed to therapies involving bulking agents.
However, most stem cell harvesting protocols require
invasive procedures and/or result in harvesting of low cell
numbers. Recently, hAFSCs have been proposed as a pro-
mising stem cell source for various cell therapies and tis-
sue engineering. These cells can be obtained non-
invasively and can differentiate into multiple cell lineages,
such as adipocytes [7], osteoblasts [7], chondrocytes [13],
renal cells [14], hepatocytes [4] and cardiomyocytes [15].
In the present study, we obtained a homogeneous gen-
otypic cell profile using a double sorting procedure with
C-KIT antibody. FACS analysis showed the hAFSCs
were positive for mesenchymal stem cell markers,
including SSEA4, CD44, CD73, CD90 and CD105, and
the expression levels were similar to previous reports
[7,16]. The hAFSCs showed negative expression for
hematopoietic stem cell marker CD45. These results
suggest that the hAFSCs were of the mesenchymal stem
cell and not hematopoietic stem cell lineage.
When cultured in myogenic induction media, hAFSCs
differentiated into muscle progenitor cells. During differ-
entiation, expression of early myogenic differentiation
Figure 2 Myogenic differentiation of hAFSCs in vitro. (A) Viability assay for cells cultured in three different myogenic induction media for 14
days. Cell viability in CM was 2.7- (P < 0.0001) and 1.58- (P < 0.0001) fold higher than that of cells cultured in medium containing 5-azaC or
TGF-b respectively. (B) Real-time PCR analysis of expression of myogenic lineage markers in three different media at Days 3 and 7. The
expression of early myogenic differentiation markers (PAX7 and MYOD) was dominant at Day 3 and the expression of the mid to late myogenic
marker (DYSTROPHIN) became dominant at Day 7 (**P < 0.01; *P < 0.05). (C) Double staining using primary myogenic antibodies and DAPI
through ICC analysis (200×) at Day 7. Cells were strongly positive for MYOD and DESMIN. Ctrl(+), positive control C2C12 cells; Ctrl(-), negative
control with human fibroblasts.
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markers (PAX7 and MYOD) decreased gradually, and
expression of the middle (DESMIN) and late (DYSTRO-
PHIN) differentiation markers increased over time.
Culture media containing 5-azaC and TGF-b induced a
similar level of myogenic differentiation as did CM treat-
ment. However, cell viability was significantly enhanced
with CM treatment. These results suggest that hAFSCs
have myogenic potential and that CM might be the best
medium for induction of myogenic differentiation.
We also evaluated the therapeutic feasibility of periure-
thral injection of hAFSCs in an SUI animal model. When
hAFSCs were injected into the animal, IHC staining with
HuNu confirmed that the injected cells were able to sur-
vive in the host environment. They integrated into the
mouse sphincter muscle layer and survived within these in
vivo conditions for 14 days. Real-time PCR gave us valuable
information on the interaction between human cells and
mouse cells. Human myogenic gene expression gradually
decreased over time, while mouse gene expression steadily
increased. These results indicate the grafted hAFSCs might
have undergone in situ myogenic differentiation and
induced host muscle regeneration. These findings are simi-
lar to other reports of human stem cell transplantation
into animals [17-19]. The details underlying the specific
mechanism of action need to be investigated.
Clinically, SUI can occur acutely or chronically in
humans. Chronic SUI, which usually occurs in the
female population, is commonly caused by weakness of
urethral sphincter muscle owing to vaginal delivery, for
example. Meanwhile, acute SUI can be induced by ure-
thral sphincter muscle resection or atrophy, after pros-
tate surgery in males or perineal trauma. In all cases, we
can expect improvements of incontinence if urethral
sphincter muscle is restored morphologically and func-
tionally. We observed sphincter muscle atrophy after
bilateral pudendal nerve transection in this study and
we confirmed the regeneration of urethral sphincter
muscle after cell injection in vivo. Although our animal
model is closer to acute SUI rather than chronic SUI,
we believe this therapeutic method can improve both
chronic and acute SUI by functional restoration of ure-
thral sphincter muscle.
The wide use of human stem cells for therapeutic appli-
cation has prompted the search for non-invasive methods
for tracking injected cells. For example, Delo et al. devel-
oped an MRI-based cell tracking method [20], and were
able to detect injected hAFSCs up to four weeks. However,
this method requires expensive high resolution MRI and
has a potential radiation hazard. In the present study, we
established an optical imaging-based cell tracking method
by labelling cells with MNPs@SiO2 (RITC). AFSCs were
labeled with nanoparticles without signs of cytotoxicity.
The labeled cells were detected for up to 10 days after
injection using optical imaging. At Day 14, the signal
strength was under the detection range. These results sug-
gest that MNPs@SiO2 (RITC) can be used for noninvasive
in vivo tracking of injected hAFSCs. A limitation of optical
imaging is that the detector could not catch the signal
when the signal strength was under the detection range.
We assumed the signal strength at Day 14 was out of the
optical imaging range. We, therefore, performed real-time
PCR to confirm longer detection of muscle regeneration.
Histological and IHC analysis showed that periurethral
injection of hAFSCs into denervated urethral sphincter
Figure 3 Identification of hAFSCs in situ with IHC staining. (A) HuNu expression of hAFSCs in vitro (200×). (B) Localization of the injected
hAFSCs. At Day 3, the injected cells were detected focally at the injection site. They migrated into surrounding tissue from Day 5 and cell
signals were gradually decreased from Day 7 (200×). Ctrl (-), negative control without cell treatment.
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Figure 4 Non-invasive cell tracking of MNPs@SiO2 (RITC) labeled hAFSCs. (A) Fluorescence image of hAFSCs labeled with MNPs@SiO2
(RITC). Following treatment, nanoparticles entered the cytoplasm. The optimum concentration of MNPs@SiO2 (RITC) was 0.1 mg/mL with a
treatment time of 24 hours. (B) FACS analysis showed labeling in 94.31% of cells. (C) Cell proliferation assays at various concentrations and
exposure times. (D) In vivo cell tracking of nanoparticle-labeled hAFSCs. The cells could be tracked with optical imaging up to 14 days after
injection. (E) HuNu was used to monitor hAFSCs migration into other organs. IHC staining revealed no positive expression in the liver, bladder,
or kidney.
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Figure 5 LPP and CP measurement. LPP and CP were measured one, two and four weeks after injection. Mean LPP and CP were significantly
higher in hAFSC-injected animals than in animals without cell injection. Ctrl, positive control with sham operation; Cell (-), pudendal neurectomy
without cell injection; Cell (+), pudendal neurectomy with hAFSCs injection (**P < 0.01; *P < 0.05). For LPP, Ctrl vs. Cell(-) and Cell (+) at Week 1,
P = 0.0009 and 0.0015; Ctrl vs. Cell (-) and Cell (+) at Week 2, P = 0.0015 and 0.002; Cell(-) vs. Cell(+) at Week 2, P = 0.009; Ctrl vs. Cell(-) at Week
4, P = 0.0052; Cell (-) vs. Cell (+) at Week 4, P = 0.024. For CP, Ctrl vs. Cell (-) and Cell (+) at Week 1, P = 0.0016 and 0.0021; Ctrl vs. Cell (-) at
Week 2, P = 0.0025; Cell (-) vs. Cell (+) at Week 2, P = 0.009; Ctrl vs. Cell (-) at Week 4, P = 0.0358; Cell (-) vs. Cell (+) at Week 4, P = 0.036.
Figure 6 Anatomical, histological and IHC analysis of regenerated sphincters. (A) Anatomic location of the urethral sphincter and cell
injection. Location of the urethral sphincter on mouse model (upper) and cell injection on the urethral sphincter area using a Hamilton
microsyringe (lower). (B) The sphincter of hAFSCs-injected animals showed apparently normal muscle regeneration with strong MyoD and
myosin heavy chain (MHC) expression. The Cell (-) group showed atrophic sphincters. Ctrl, positive control with sham operation; Cell (-),
pudendal neurectomy without cell injection; Cell (+), pudendal neurectomy with hAFSCs injection (200×).
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stimulated normal-appearing sphincter muscle regenera-
tion over time. These results correlated well with the
real-time PCR analysis for myogenic gene expressions over
time. The functional analysis of the sphincters showed that
LPP and CP of the hAFSC injected group were restored to
nearly normal values, while the Cell (-) group values
Figure 7 Real-time PCR analysis of regenerated sphincter. (A) Human gene expression was highest at the first week and gradually
decreased with time (**P < 0.01; *P < 0.05). (B) Mouse gene expression was gradually increased with time (**P < 0.01; *P < 0.05). (C) Detection
of the neuromuscular junction with a-Bungarotoxin staining. A regenerated neuromuscular junction was detected by the presence of an
acetylcholine receptor. (D) Neurogenic marker gene expression was analyzed with real-time PCR. Significantly enhanced gene expression was
seen in the cell-injected group compared with the non-injected group (**P < 0.01; *P < 0.05). –, pudendal neurectomy without cell injection; +,
pudendal neurectomy with hAFSCs injection
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remained low throughout the study period. These results
indicate that periurethral injection of hAFSCs into a
denervated urethral sphincter can restore apparently nor-
mal urethral sphincter histology and function.
Restoration of sphincter function requires regenera-
tion of a neuronal component (neuromuscular junction
and nerve regeneration) as well as muscle regeneration.
In this study, we found similar expression levels in the
Cell (+) group and the normal control, whereas the Cell
(-) group showed a higher expression level. This indi-
cates that the transplanted hAFSCs can control damaged
tissue regeneration by harmonizing the physical environ-
ment [21]. Over-proliferation or unwanted differentia-
tion can cause malignant formation. In addition,
significantly enhanced neurogenic gene expression was
seen in the Cell (+) group compared with the Cell (-)
group. This result suggests that injected cells can have a
physiologic effect on the neuromuscular junction re-for-
mation and nerve regeneration.
Recently, several reports have suggested that stem cells
may have a low immunogenicity and immunomodulatory
function [22,23]. In this study, we found that hAFSCs have
a lower expression of HLA-DR compared with isotope
control. Furthermore, injection of hAFSCs into ICR mice
also did not stimulate CD8+ T cell infiltration into the
injected area. These findings suggest that hAFSCs have an
immune tolerance and/or immunosuppression effect,
similar to that reported for other stem cells. When
injected into the renal subcapsule, hAFSCs did not cause
teratomas after eight weeks. This result supports the use
Figure 8 Immunogenicity and tumorigenicity of hAFSCs. (A) FACS analysis for HLA-DR expression. HLA-DR expression in hAFSCs was lower
than isotype (negative control with PE-conjugated antibody). (B) IHC staining of a retrieved urethral sphincter one week after hAFSCs injection.
The cell-injected animal showed scant CD8 lymphocyte aggregation, while the cell (-) and human fibroblast-injected animals had significant CD8
lymphocyte accumulation (200×). Cell (-), pudendal neurectomy without cell injection; Cell (+), pudendal neurectomy with cell treatment; Ctrl(+),
positive control with human fibroblast injection (200×). (C) H&E stain of kidney tissue retrieved eight weeks after renal subcapsular injection of
hAFSCs. No teratoma formation was found at the injection site (100× and 200×).
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of hAFSCs as a safe for cell therapeutic application in
terms of tumorigenicity.
The limitations of this study include the lack of identifi-
cation of a precise mechanism for a paracrine effect, nerve
regeneration, and the inability to track the metabolism or
fate of the injected cells in vivo.
Conclusions
We were able to isolate homogenous hAFSCs possessing
mesenchymal stem cell characteristics and these cells had
the potential to differentiate into a myogenic lineage in
vitro. We established a successful non-invasive in vivo cell
tracking procedure and used it to follow hAFSCs injected
into the denervated urethral sphincter. These cells pro-
moted regeneration of urethral sphincter muscle, morpho-
logically and functionally similar to the normal urethral
sphincter, apparently through in situ differentiation and
host cell stimulation by the hAFSCs. The xenograft hAFSC
transplantation did not cause any immune response or
tumor formation at the injection site. Therefore, hAFSCs
appear to be a promising cell source for SUI stem cell
therapy.
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